Trial Profile

The Benralizumab Pregnancy Exposure Study: A VAMPSS Post Marketing Surveillance Study

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 29 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Benralizumab (Primary)
Indications Asthma
Focus Adverse reactions
Acronyms VAMPSS
Sponsors AstraZeneca

Most Recent Events

23 Apr 2024 Status changed from recruiting to discontinued. (The decision to terminate the Fasenra pregnancy study and cancel the commitment to conductadditional pregnancy-related pharmacovigilance activities was made by the EMA following MAH'sfailed attempts to address patient recruitment challenges)
22 Jul 2020 Planned End Date changed from 28 Feb 2026 to 27 Feb 2026.
22 Jul 2020 Planned primary completion date changed from 28 Feb 2026 to 27 Feb 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com